206-838-5110 ext. 102 general@etubics.com

Cancer Breakthroughs 2020

Etubics Corporation is pleased to announce our participation in the Cancer Breakthroughs 2020 program. We will be joining multinational pharmaceutical, biotechnology and insurance companies, academic cancer research centers and oncologists in an effort to collaborate on the research and development of combination immunotherapy treatments. Cancer Breakthroughs 2020 will focus on designing, initiating and completing randomized clinical trials at all stages of cancer in 20 tumor types in as many as 20,000 patients in the next 36 months. The goal of this program is to accelerate the potential of cancer immunotherapies as the new standard of treatment for patients with cancer. For more information regarding the Cancer Breakthroughs 2020 program, please visit: http://www.cancerbreakthroughs2020.org/
We are excited to be chosen to participate in this program.

Contact Us

(206) 838-5110 ext. 102

For more information on Cancer Breakthroughs visit: cancer breakthroughs 2020.org